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Abstract
 
During human pregnancy, the specialized epithelial cells of the placenta (cytotrophoblasts) come
into direct contact with immune cells in several locations. In the fetal compartment of the pla-
centa, cytotrophoblast stem cells lie adjacent to macrophages (Hofbauer cells) that reside within
the chorionic villus stroma. At sites of placental attachment to the mother, invasive cytotropho-
 
blasts encounter specialized maternal natural killer (NK) cells (CD56
 
bright
 
), macrophages, and T
cells that accumulate within the uterine wall during pregnancy. Here we tested the hypothesis
that fetal cytotrophoblasts can direct the migration of these maternal immune cells. First, we as-
sayed the chemotactic activity of cytotrophoblast conditioned medium samples, using human
peripheral blood mononuclear cells as targets. The placental samples preferentially attracted NK
cells (both CD56
 
dim
 
 and CD56
 
bright
 
), monocytes, and T cells, suggesting that our hypothesis was
 
correct. A screen to identify chemokine activity through the induction of a Ca
 
2
 
1
 
 flux in cells
transfected with individual chemokine receptors suggested that cytotrophoblasts secreted mono-
 
cyte inflammatory protein (MIP)-1
 
a
 
. This was confirmed by localizing the corresponding
mRNA and protein, both in vitro and in vivo. MIP-1
 
a
 
 protein in conditioned medium was
further characterized by immunoblotting and enzyme-linked immunosorbent assay. Immunode-
pletion of MIP-1
 
a
 
 from cytotrophoblast conditioned medium showed that this chemokine was
responsible for a significant portion of the induced monocyte and CD56
 
bright
 
 NK cell chemotax-
is. These data suggest the specific conclusion that cytotrophoblasts can attract monocytes and
CD56
 
bright
 
 NK cells by producing MIP-1
 
a 
 
and the more general hypothesis that these cells may
organize and act on leukocytes at the maternal–fetal interface.
Key words: chemokine • pregnancy • leukocyte • immune tolerance • trophoblast
 
Introduction
 
Early in human pregnancy, as part of a process known as
decidualization, maternal leukocytes traffic to the uterus,
where the fetal-derived placenta has implanted. The histol-
ogy of this area is diagrammed in Fig. 1 (see also references
1–4). The placenta is made up of individual units termed
chorionic villi. Each villus has a connective tissue core that
contains fetal blood vessels and numerous macrophages,
termed Hofbauer cells. The macrophages often lie adjacent
to a thick basement membrane, which underlies a layer of
cytotrophoblast stem cells that are the progenitors of all the
trophoblast lineages.
The differentiation pathway taken by the cytotropho-
blast stem cells depends on their location. In floating villi,
the cytotrophoblasts fuse to form a multinucleate syncytial
covering. These villi are attached at only one end to the
tree-like fetal portion of the placenta. The rest of the villus
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floats in a stream of maternal blood, which optimizes ex-
change of substances between the mother and fetus across
the syncytium. In anchoring villi, cytotrophoblast stem
cells detach from the basement membrane and form a col-
umn of nonpolarized mononuclear cells that invade the
uterus. As a result, these villi are attached at one end to
the fetal portion of the placenta and at the other end to the
uterus. This arrangement anchors the villus to the uterine
wall. Invasive cytotrophoblasts rapidly traverse most of the
uterine parenchyma (interstitial invasion). They also breach
the uterine veins and arteries they encounter (endovascular
invasion). Their interactions with veins are confined to the
portions of the vessels that lie near the inner surface of the
uterus, but beginning in the second trimester, cytotropho-
blasts migrate in a retrograde direction along much of the
intrauterine course of the arterioles. Eventually, these fetal
cells completely replace the maternal endothelial lining and
partially disrupt the muscular wall of these vessels. This un-
usual process diverts uterine blood flow to the floating villi.
Endovascular invasion places fetal cells from the placenta
in direct contact with maternal blood in the uterine vessels.
Our previous work shows that endovascular cytotropho-
blasts modulate their adhesion molecule phenotype to re-
semble that of endothelial cells, a phenomenon we termed
pseudovasculogenesis (4). Interstitial invasion brings cy-
totrophoblasts into direct contact with maternal immune
cells in the uterus, termed decidual granulated leukocytes
(DGLs).
 
1
 
 Both invasive cytotrophoblasts and DGLs have
unusual immunological properties. For example, the fetal
cells express the nonclassical MHC class Ib molecules
HLA-G and HLA-E, rather than the classical molecules
 
HLA-A and -B (5–8). The expression of HLA-C by cy-
totrophoblasts has also been reported (9). The maternal
DGLs have an unusual composition: 
 
z
 
70% are specialized
(CD56
 
bright
 
CD16
 
2
 
) NK cells, and the remainder include
equal contributions of monocytes (
 
z
 
15%) and T cells
(
 
z
 
15%) (10). During the first half of human pregnancy,
DGLs account for a significant portion of the maternal cells
within the uterus (11). This phenomenon is not unique to
humans, as recruitment of uterine NK cell populations dur-
ing pregnancy has also been described in mice (12–14) and
pigs (15, 16). Although the functional consequences of cy-
totrophoblast interactions with DGLs are not well under-
stood, experimental evidence in mice suggests that the im-
mune cells promote endovascular invasion and placental
development (17, 18). This idea is in accord with observa-
tions in other tissues that immune cells, primarily macro-
phages, secrete trophic factors that promote the growth and
differentiation of resident cells (19–21).
The mechanisms underlying DGL recruitment to the
uterus during pregnancy are not understood, but in the
context of their known functions, chemokines are likely to
be involved. Chemokines are a family of structurally re-
lated molecules that mediate immune cell trafficking to
sites of inflammation (22) and to secondary lymphoid or-
gans (23). Here we used an in vitro model to test the hy-
pothesis that chemokines derived from fetal cytotropho-
blasts play a role in maternal DGL trafficking to the uterus
during pregnancy. In this model, samples of human cy-
totrophoblast conditioned medium (CM) and human pe-
ripheral blood leukocytes were placed on opposite sides of
a Transwell filter membrane. We found that the medium
samples recruited a leukocyte population with a composi-
tion that was very similar to that of DGLs. Then, we
used this model to show that a cytotrophoblast-derived
chemokine, monocyte inflammatory protein 1
 
a
 
 (MIP-
 
1
 
Abbreviations used in this paper:
 
 CM, conditioned medium; DGLs, decid-
ual granulated leukocytes; MIP-1
 
a
 
, monocyte inflammatory protein 1
 
a
 
;
SFM, serum-free medium.
Figure 1. The cellular architec-
ture of the human maternal–fetal in-
terface where fetal placental cells
(cytotrophoblasts) are in close prox-
imity to maternal leukocytes that re-
side within the uterine wall. The
chorionic villus is the basic structural
unit of the placenta. A subset,
termed anchoring chorionic villi
(AV), establishes physical connec-
tions between the fetus and the
mother. Anchoring villi form when
cytotrophoblast stem cells detach
from their basement membrane and
form a column of nonpolarized
mononuclear cells that invade the
uterus. These invasive cytotropho-
blasts rapidly traverse most of the
uterine parenchyma, where they en-
counter numerous maternal immune
cells, predominantly CD56bright NK
cells, but also macrophages and
T cells. Invasive cytotrophoblasts
target uterine spiral arterioles for in-
vasion. They remodel these vessels by replacing the endothelial lining and destroying the muscular wall. Thus, cytotrophoblasts are in direct contact with
both maternal peripheral blood (sites marked 1) and decidual leukocytes (sites marked 2). FV, floating villi. 
1201
 
Drake et al.
 
1
 
a
 
), is one of the factors in the CM that plays a major role
in attracting monocytes and NK cells in vitro. Since we
also detected expression of MIP-1
 
a
 
 mRNA and protein in
cytotrophoblasts in situ at the human maternal–fetal inter-
face, we hypothesize that this chemokine has similar effects
during pregnancy.
 
Materials and Methods
 
Collection of Human Placentas and Leukocytes.
 
Studies involv-
ing placental tissues were approved by the University of Califor-
nia at San Francisco (UCSF) Institutional Review Board. Placen-
tas were from patients who had elective pregnancy terminations
(6–22 wk) or normal term deliveries. The tissue was immediately
collected into PBS with antibiotics (1% penicillin/streptomycin
and 1% gentamicin), washed in the same solution, and briefly
stored on ice before processing. Human leukocytes were ob-
tained from Blood Centers of the Pacific, San Francisco, CA. No
information was available regarding the sex, age, or pregnancy
status of the blood donors.
 
Isolation and Culture of Placental Cells.
 
Cytotrophoblasts were
isolated from pools of first or second trimester placentas or from
individual third trimester placentas as described previously (24–
26). Briefly, placentas were subjected to a series of enzymatic
digestions, which detached cytotrophoblast stem cells from the
underlying stromal cores of the chorionic villi. Detached cytotro-
phoblasts were isolated on a Percoll gradient, and remaining
leukocytes were extracted by virtue of their interactions with
CD45-coated beads, which were then removed with a magnetic
device (Dako). The final purity of the cells was 90–95%, with
CD45
 
1
 
 cell contamination 
 
,
 
5%. The cells were cultured on
Matrigel-coated substrates (Collaborative Biomedical Products) in
serum-free medium (SFM): DMEM 4.5 g/liter glucose (Sigma-
Aldrich), supplemented with 2% Nutridoma (Boehringer Mann-
heim), 1% penicillin/streptomycin, 1% sodium pyruvate, 1%
Hepes, and 1% gentamicin (UCSF Cell Culture Facility). After
12, 24, 36, and 48 h in culture, the CM was removed, passed
through a 0.2-
 
m
 
m filter, and stored at 
 
2
 
20
 
8
 
C before use. To pre-
pare control SFM (SFM/MG), Matrigel-coated plates were incu-
bated without cells in medium for the times indicated above. Pla-
cental fibroblasts were isolated from denuded connective tissue
villus cores as described previously (25). The cells were main-
tained in DMEM H-21 containing 10% FBS, 5% glutamine, 1%
penicillin/streptomycin, and 1% gentamicin. The JAR human
choriocarcinoma cell line was maintained as described previously
(25).
 
Isolation of Human PBMCs.
 
Human PBMCs were prepared
from a buffy coat by erythrocyte sedimentation with 6% dextran
T500 (Amersham Pharmacia Biotech) followed by Histopaque-
1077 (Sigma-Aldrich) separation. PBMCs were washed in PBS
and resuspended at 10
 
7
 
 cells/ml in DME-H21 (UCSF Cell Cul-
ture Facility) containing 1.0% BSA (Sigma-Aldrich).
 
Chemotaxis Assay.
 
Chemotaxis assays were performed ac-
cording to published methods (27). CM with initial MIP-1
 
a
 
concentrations of between 50 and 100 ng/ml as determined by
ELISA (see below) were used in the assay. In some cases, up to
seven cytotrophoblast CM samples were pooled according to ges-
tational age in trimesters and concentrated with a Centriprep-3
centrifugal concentrator (Amicon Inc.). The CM was diluted
with DME-H21 (UCSF Cell Culture Facility) containing 1.0%
BSA (Sigma-Aldrich), hereafter referred to as blank medium, to
produce samples with MIP-1
 
a
 
 concentrations ranging from 100
 
ng/ml to 10 pg/ml. Transwell inserts (6.5 mm in diameter, 5-
 
m
 
m
pore; Corning Inc.) were placed in 24-well plates. 600 
 
m
 
l of cy-
totrophoblast CM, blank medium, or blank medium supple-
mented with recombinant human MIP-1
 
a
 
 (R&D Systems) was
added to the bottom compartment of each insert, and 100 
 
m
 
l of a
human PBMC cell suspension containing 10
 
6
 
 cells was added to
the top. Where indicated, 5 
 
m
 
g/ml of control goat IgG (R&D
Systems) or anti–MIP-1
 
a
 
 IgG that neutralized activity (R&D
Systems) was added to the cell suspension. Negative controls in-
cluded blank medium and SFM/MG. Positive controls included
blank medium to which recombinant MIP-1
 
a
 
 was added at con-
centrations ranging from 100 ng/ml to 10 pg/ml. After incuba-
tion for 3 h at 37
 
8
 
C in a standard tissue culture incubator, the
Transwell inserts were removed and a known number of 15-
 
m
 
m
microsphere beads (Bangs Laboratories) was added to the wells
before the medium and cells in the bottom compartment were
transferred to polystyrene tubes. Cells and beads were pelleted by
centrifugation (300 
 
g
 
; 10 min). All but 100–200 
 
m
 
l of the super-
natant was removed, and fluorochrome-conjugated antibodies
recognizing CD14 (which labels monocytes), CD56 (which la-
bels NK cells), and CD3 (which labels T cells) (Becton Dickin-
son) were added to the tubes, which were then incubated at 4
 
8
 
C
in the dark for 1 h. Cells were washed twice in PBS containing
2% FCS. The mixture of cells and beads was analyzed by flow
cytometry on a FACScan™ (Becton Dickinson) with
CELLQuest™ software (Becton Dickinson). The absolute num-
ber of cells that migrated was extrapolated from the percent re-
covery of the beads. All assays were done in triplicate.
 
Ca
 
2
 
1
 
 Flux Assays.
 
Reporter cell lines were generated as de-
scribed previously (28–30). HEK-293 parental cells were trans-
fected with human CCR1 (31–33) and CCR2 (28, 34, 35), and
300-19 parental cells were transfected with CCR3 (36–39),
CCR5 (40, 41), and CX3CR1 (42, 43). The nontransfected
parent lines served as negative controls. Prior to analyses, me-
dium samples were concentrated 5–10-fold (vol/vol) over a
heparan sulfate column according to the manufacturer’s direc-
tions (Amersham Pharmacia Biotech), after which they were di-
alyzed against PBS overnight at 4
 
8
 
C. Intracellular Ca
 
2
 
1
 
 release
was monitored as described previously (28). Briefly, the target
cells were preloaded with the Ca
 
2
 
1
 
-sensitive dye calcein AM
(Molecular Probes Inc.), washed, and resuspended in 1 
 
m
 
l of
RPMI 1640. The experiment started with the addition of 20 
 
m
 
l
of concentrated cytotrophoblast CM, 20 
 
m
 
l of concentrated
SFM/MG as a negative control, or 5 
 
m
 
l of a stock solution (10
mM) of the relevant recombinant chemokine as a positive con-
trol (MIP-1
 
a
 
, MCP-1, eotaxin, RANTES [regulated on activa-
tion, normal T cell expressed and secreted], or fractalkine). The
magnitude of the Ca
 
2
 
1
 
 flux was determined spectrophotometri-
cally.
 
In Situ Hybridization.
 
In situ hybridization was performed us-
ing published methods (44). Isolated cytotrophoblasts were cul-
tured (as described above) on a 200-
 
m
 
l plug of Matrigel in a Mil-
licell-CM culture insert, 12 mm in diameter, 0.4-
 
m
 
m pore
(Millipore). After 24 h in culture, the cells, together with the
Matrigel substrate, were dissected from the inserts and fixed in 3%
paraformaldehyde for 30 min at 4
 
8
 
C. Then the cytotrophoblasts
and Matrigel were subjected to an increasing gradient of sucrose
in PBS. After 20 min each in 5, 10, and 15% sucrose, the cells
were incubated overnight in a 1:1 (vol/vol) mixture of optimum
cutting temperature (OCT) compound and 15% sucrose. The
next day, the cell plug was embedded in OCT and frozen in liq-
uid nitrogen. 5-
 
m
 
m sections were cut, mounted on poly-
 
l
 
-
lysine–coated slides, and stored at 
 
2
 
20
 
8
 
C until use. 
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Tissue specimens (
 
n
 
 
 
5 
 
9) for in situ hybridization were fixed
with 10% formalin in PBS at room temperature overnight,
washed twice in PBS, dehydrated through a graded ethanol series,
cleared in xylene, and paraffin embedded. 5-
 
m
 
m sections were
cut and mounted on poly-
 
l
 
-lysine–coated slides, deparaffinized,
and rehydrated before use.
To produce labeled probes, the EST plasmid clone ID no.
154848, which contains an 837-bp insert of the human MIP-1
 
a
 
cDNA, was cut with either NotI or EcoRI (GIBCO BRL). The
linearized vectors were used as templates for the synthesis of 
 
35
 
S-
labeled cRNA probes using T3 (antisense) or T7 (sense) RNA
polymerases (45).
On day 1 of the in situ hybridization, slides were allowed to sit
at room temperature for 5 min. They were then placed in PBS
for 5 min, before incubation at room temperature in 4% parafor-
maldehyde in PBS for 10 min, followed by a 5-min wash in 0.5
 
3
 
SSC (1
 
3
 
 
 
5 
 
150 mM NaCl, 15 mM sodium citrate, pH 7.4). Sec-
tions were deproteinated with 1 
 
m
 
g/ml proteinase K for 10 min
at room temperature and then washed for 10 min in 0.5
 
3
 
 SSC.
They were fixed again in 4% paraformaldehyde for 3 min, fol-
lowed by a final wash in 0.5
 
3
 
 SSC for 5 min. After a 3-h prehy-
bridization at 55–60
 
8
 
C in rHB2 buffer (50% formamide, 0.3 M
NaCl, 20 mM Tris, pH 8.0, 5 mM EDTA, 1
 
3
 
 Denhardt’s
[0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA], 10%
dextran sulfate, 10 mM dithiothreitol), the slides were incubated
overnight at 55–60
 
8
 
C in a humidified chamber with 200 
 
m
 
l of
hybridization buffer: rHB2 buffer containing 500 
 
m
 
g/ml yeast
tRNA and 1,200,000 cpm of 35S-labeled antisense (experimental)
or sense (negative control) cRNA probes. After hybridization,
sections were washed twice, 10 min each, in 23 SSC (300 mM
NaCl, 30 mM sodium citrate) with 10 mM b-mercaptoethanol
and 1 mM EDTA. Slides were then immersed in an RNaseA so-
lution (500 mM NaCl, 10 mM Tris, pH 8.0, and 10 mg/ml
RNaseA) for 30 min at room temperature and washed twice, 10
min each, in 23 SSC/b-mercaptoethanol/EDTA. The sections
were then subjected to a high stringency wash (0.13 SSC, 10
mM b-mercaptoethanol, 1 mM EDTA) for 2–3 h at 608C before
they were washed twice, 10 min each, in 0.53 SSC without
b-mercaptoethanol or EDTA. Finally, the sections were dehy-
drated (2 min per step) in a series of graded (30, 60, 80, 95, and
100%) ethanol solutions that contained 0.3 M NH4Ac. The slides
were dried for 2 h in a fume hood before being dipped in Kodak
NTB-2 liquid emulsion. Afterwards they were dried overnight in
the dark, boxed, and stored at 48C until they were developed.
The sections were stained with hematoxylin and eosin before
they were examined in both dark and bright field using a Zeiss
Axiophot microscope.
Immunohistochemistry. Antibodies included anticytokeratin,
7D3 rat antihuman (46); anti-CD45Rb, PD7/26 mouse antihu-
man (Dako); anti–MIP-1a, C-16 goat antihuman (Santa Cruz
Biotechnology); FITC-conjugated donkey antimouse; and rho-
damine-conjugated donkey antirat (Jackson ImmunoResearch
Laboratories). For staining of in vitro cultures, sections of cell ag-
gregates were prepared as described above, and then antibody
binding was detected using VECTASTAIN® ABC kits (PK-6102
and PK-6104; Vector Laboratories) according to the manufac-
turer’s instructions. Signal was detected with a DAB peroxidase
substrate kit (Vector Laboratories). As a negative control, primary
antibody was omitted on some sections. Slides were counter-
stained with hematoxylin and eosin before analysis. For staining
of intact tissues, specimens were fixed in 3% paraformaldehyde
for 5 min, flash frozen in liquid nitrogen, and sectioned (5 mm).
Slides were immersed in ice cold methanol for 10 min, washed in
PBS, and exposed to primary antibody (1:25 dilution) for 4 h.
Slides were then washed in PBS and incubated with secondary
antibody (1:100 dilution) for 1 h, washed in PBS, and mounted
with VECTASHIELD® mounting medium (Vector Laborato-
ries). Negative controls included specimen incubation with nor-
mal goat serum.
Northern Hybridization. Total RNA was extracted from cy-
totrophoblasts immediately after the cells were isolated or after
12, 24, or 36 h in culture, according to published methods (47).
Blots were prepared as follows. 10 mg of total RNA was sepa-
rated by formaldehyde–agarose gel electrophoresis, transferred to
Nytran membranes (Schleicher and Schuell, Inc.), and analyzed
by Northern blot hybridization as described previously (48–50).
Gels were stained with acridine orange before transfer to ensure
integrity of the RNA samples and to confirm that equal amounts
of RNA had been loaded in each lane. The MIP-1a–specific
probe (see above) was generated by using standard methods (51).
[32P]CTP random oligonucleotide primers (Amersham Life Sci-
ence, Inc.) and the Klenow fragment of DNA polymerase I
(GIBCO BRL) were used to label the probe, which had a spe-
cific activity of 2 3 109 dpm/mg.
Immunoblotting. Samples of cytotrophoblast CM were con-
centrated by heparin affinity chromatography as described above.
Proteins were separated by SDS-PAGE on 10% gels and trans-
ferred to nitrocellulose membranes (Schleicher and Schuell, Inc.).
Nonspecific antibody binding was blocked by incubating the
membranes for 1 h at room temperature in MT-PBS: PBS con-
taining 5% nonfat dried milk (Carnation Nestle USA Inc.), and
0.1% Tween-20 (Sigma-Aldrich). The membranes were incu-
bated overnight at 48C with the primary antibody, anti–MIP-1a
goat polyclonal IgG (C-16; Santa Cruz Biotechnology) diluted
1:20 (vol/vol) in MT-PBS. The membranes were washed three
times, 10 min each, in PBS containing 0.1% Tween-20 (T-PBS)
before they were incubated for 1 h at room temperature in the
secondary antibody, horseradish peroxidase–conjugated donkey
anti–goat IgG (Jackson ImmunoResearch Labs Inc.) diluted 1:3,000
(vol/vol) in MT-PBS. Finally, the membranes were washed three
times, for 10 min each, in T-PBS and processed for detection of
bound antibody by chemiluminescence according to the manu-
facturer’s instructions (ECL; Amersham Pharmacia Biotech).
ELISA. ELISA kits for quantifying human MIP-1a (catalog
no. DMA00) were purchased from R&D Systems, and the assays
were performed according to the manufacturer’s instructions.
Endotoxin Detection. The Endotoxin Detection Kit (catalog
no. 3070000) from ICN Pharmaceuticals, Inc. was used accord-
ing to the manufacturer’s instructions.
Statistical Analysis. To describe the general effects of cytotro-
phoblast CM on cell migration, data from all chemotaxis experi-
ments were analyzed together. Because the data were nonpara-
metrically distributed, the results were reported as the median and
interquartile range. To determine the significance of the effect of
neutralizing the MIP-1a in the chemotaxis assays, each experi-
ment was considered individually. Data within individual experi-
ments were normally distributed and were analyzed with a two-
tailed Student’s t test. Subsequently, the mean percentage change
(and standard deviation) in migration due to addition of a neu-
tralizing antibody was calculated for all experiments. For ELISA,
analysis of variance, followed by a Student-Newman-Keuls test,
was used to compare the concentration of MIP-1a in medium
from first trimester, second trimester, and term cytotrophoblasts.
The Spearman Rank Order Correlation was used to test for a
trend between presence of endotoxin and levels of MIP-1a in
cytotrophoblast CM.1203 Drake et al.
Results
Cytotrophoblast CM Attracts NK Cells, Monocytes, and T
Cells. As an initial test of our hypothesis that placental
cells can direct the migration of decidual leukocytes, we
characterized the chemoattractant properties of CM har-
vested from cultures of primary cytotrophoblasts, using hu-
man PBMCs as targets. Freshly isolated cytotrophoblasts
are a mixture of stem cells and cells in the initial stages of
differentiation. After 24–48 h in culture, the cytotropho-
blasts have fully differentiated along the pathway that leads
to invasion of the uterine wall, a process that places them in
direct contact with resident maternal cells, including leuko-
cytes (for review see reference 4). Thus, CM samples were
harvested after the cells had been in culture for .12 h. Pre-
liminary experiments showed that cytotrophoblast CM iso-
lated from first, second, and third trimester placentas in-
duced the chemotaxis of monocytes, NK cells, and T cells
from peripheral blood. The results suggested that cytotro-
phoblasts produce soluble factors that can direct the migra-
tion of leukocytes found at the maternal–fetal interface
during pregnancy.
A Chemokine in Cytotrophoblast CM Signals through MIP-
1a Receptors. Next, we investigated whether the chemo-
tactic factors in the CM included chemokines. Cell lines
transfected with individual chemokine receptors were chal-
lenged with cytotrophoblast CM that was concentrated
over a heparan sulfate column. Positive controls included
exposure of each cell line to a ligand that activated the rele-
vant receptor. Cells expressing one of the following re-
ceptors were exposed to the ligand indicated: CCR1/
RANTES, CCR2/MCP-1, CCR3/eotaxin, CCR5/MIP-
1a, and CX3CR1/fractalkine. In all cases, addition of the
recombinant chemokine induced a robust Ca21 influx in
the transfected line (data not shown). Negative controls in-
cluded exposure of the transfected cells to serum-free con-
trol medium incubated on Matrigel in the absence of cells
(SFM/MG) and addition of cytotrophoblast CM to the
corresponding untransfected parental cell line.
Results typical of these experiments are summarized in
Fig. 2. Concentrated cytotrophoblast CM, but not concen-
trated SFM/MG, induced a Ca21 flux in cells expressing
CCR1 (Fig. 2 A; n 5 4) and CCR5 (Fig. 2 B; n 5 5), but
not CCR2, CCR3, or CX3CR1 (data not shown; n 5 4,
n 5 4, and n 5 3, respectively). CM samples from all three
trimesters had the same pattern of activity, although the
magnitude of the response varied among samples. As MIP-
1a is the only chemokine that is a ligand for both CCR1
and CCR5 but not CCR3, we hypothesized that MIP-1a
was present in the CM.
Cytotrophoblasts Express MIP-1a mRNA In Vitro.  To
confirm that cytotrophoblasts secreted MIP-1a, we first
examined production of MIP-1a mRNA by isolated cells.
Initially, we used in situ hybridization for this purpose. The
cytotrophoblasts were cultured for 24 h on Matrigel, and
then the cells together with the substrate were fixed and
sectioned before hybridization (see Materials and Meth-
ods). Fig. 3 A is a photomicrograph of a histological section
of the cultured cells that was stained with hematoxylin and
eosin. The morphology is typical of cytotrophoblasts cul-
tured under these conditions (26). The cells rapidly aggre-
gate, and those in direct contact with the matrix invade the
substrate, which is no longer visible due to solubilization
during the hybridization procedure. In situ hybridization
with sense (Fig. 3 B) and antisense probes (Fig. 3 C)
Figure 2. Cytotrophoblast CM signals through MIP-1a receptors.
Cytotrophoblast (CTB) CM was screened for its ability to induce a cal-
cium flux in reporter cells transfected with individual chemokine recep-
tors. Negative controls included exposure of the transfected cells to se-
rum-free control medium incubated with Matrigel in the absence of cells
(SFM/MG) and addition of cytotrophoblast CM to the corresponding
untransfected parental cell line. Recombinant chemokines were used as
positive controls. Concentrated cytotrophoblast CM induced a Ca21 flux
in cells expressing CCR1 (A) and CCR5 (B), but not CCR2, CCR3, or
CX3CR1 (data not shown).1204 Human Placental Cells Use Chemokines to Recruit Monocytes and NK Cells
showed that cytotrophoblasts synthesize MIP-1a mRNA.
Immunohistochemistry on adjacent sections was performed
to demonstrate that the cell aggregate was composed of cy-
totrophoblasts, particularly to exclude the possibility of
macrophage contamination. The staining revealed the pres-
ence of cytokeratin, a cytotrophoblast marker (Fig. 3 D),
and the absence of CD45Rb, a marker for bone marrow–
derived cells (Fig. 3 E).
We used Northern blot hybridization to quantify cy-
totrophoblast expression of MIP-1a mRNA as a function
of differentiation/invasion in vitro. Membranes with RNA
samples isolated from first trimester cytotrophoblasts were
hybridized with a 32P-labeled cDNA probe to MIP-1a.
The results are shown in Fig. 4. Freshly isolated cytotro-
phoblasts expressed very low levels of the 800-bp mRNA
that encodes this chemokine. Expression of an RNA of the
expected size was dramatically upregulated by z30-fold af-
ter 12 h in culture. Levels remained high at the 24-h time
point and decreased after 36 h in culture. RNA samples
that were isolated from second trimester cells showed the
same upregulation of MIP-1a mRNA expression during
the first 12 h of culture. Neither placental fibroblasts nor
the choriocarcinoma (malignant cytotrophoblast) JAR cell
line expressed detectable levels of MIP-1a mRNA.
Cytotrophoblasts Express MIP-1a Protein In Vitro. We
also examined the cells’ expression of MIP-1a at the pro-
tein level, using two methods. In the first, immunoblot
analyses were performed using an MIP-1a–specific IgG.
The results are shown in Fig. 5 A. This antibody reacted
with a single band of the expected size (12 kD) in a sample
of recombinant MIP-1a. Immunoreactive bands of the
same estimated molecular mass were present in concen-
trated CM samples of cytotrophoblasts isolated from first,
second, and third trimester placentas. Neither the control
SFM/MG medium nor placental fibroblast CM (data not
shown) contained proteins that reacted with anti–MIP-1a.
We used an ELISA to quantify MIP-1a in cytotropho-
blast CM from first trimester (n 5 27), second trimester
(n 5 20), and term (n 5 13) cells that were cultured for
12–48 h. Levels of this chemokine detected in individual
samples ranged from 0.6 to 82 ng/ml (Fig. 5 B). CM from
eight preparations of first trimester and one preparation of
second trimester cytotrophoblasts contained amounts of
MIP-1a protein that were below the 175 pg/ml lower de-
Figure 3. In situ hybridiza-
tion demonstrates that cultured
cytotrophoblasts synthesize MIP-
1a mRNA in vitro. (A) Bright
field micrograph of a histological
section of cultured cytotropho-
blast cells that was stained with
hematoxylin and eosin (HE).
Dark field micrographs of control
sense probes (B) were negative,
while experimental antisense
probes (C) revealed cytotropho-
blast expression of MIP-1a
mRNA, detected as white dots
(4 wk exposure). Immunohis-
tochemistry on adjacent sections
demonstrated positive staining
for the cytotrophoblast marker
cytokeratin (CK) (D) and the ab-
sence of staining for the mac-
rophage marker CD45Rb (E).
Figure 4. Northern blot hy-
bridization shows that cytotro-
phoblasts modulate MIP-1a
mRNA expression in culture.
Top panel: Cytotrophoblast ex-
pression of MIP-1a mRNA was
quantified as a function of differ-
entiation/invasion in vitro. Total
RNA was isolated from first tri-
mester placental fibroblasts (FIB)
from the choriocarcinoma cell
line JAR, and from first (I) and
second (II) trimester cytotropho-
blasts either immediately after
isolation (0 h) or after culturing
the cells for the hours indicated.
Northern blot analysis was per-
formed using an MIP-1a–specific
probe. Prior to culture, first and second trimester cells expressed very low
levels of this mRNA, but its expression was upregulated by z30-fold after
12 h in culture. Neither placental fibroblasts nor the JAR cell line expressed
MIP-1a mRNA. Bottom panel: Acridine orange staining of the gel before
transfer demonstrated equal loading of RNA.1205 Drake et al.
tection limit of the assay. Analysis of variance, followed by
the Student-Newman-Keuls test, demonstrated that term
cytotrophoblasts produced significantly more MIP-1a (P ,
0.05) than cytotrophoblasts isolated from first and second
trimester placentas. As expected, MIP-1a was not detected
in control SFM/MG or placental fibroblast CM (data not
shown). The five pairs of connected data points in Fig. 5 B
show MIP-1a levels in medium samples from the same
culture over time. In accord with the results of the North-
ern blot hybridization analyses of MIP-1a mRNA levels,
the corresponding protein accumulated in the medium
during the course of the experiment.
To ensure that the MIP-1a detected in the CM samples
represented cytotrophoblast-derived chemokine and not
chemokine produced by contaminating monocytes within
the primary culture, we compared the levels of MIP-1a in
the medium with the presence or absence of endotoxin, a
factor that stimulates chemokine production by monocytes
but not cytotrophoblasts. 20 samples of cytotrophoblast
CM were simultaneously assayed for endotoxin by the
Limulus Amebocyte Lysate assay and for MIP-1a protein
Figure 5. Cytotrophoblasts secrete MIP-1a protein in vitro. (A) Im-
munoblotting with an MIP-1a–specific polyclonal IgG. This antibody
reacted with a single band of the expected size (12 kD) in a sample of re-
combinant MIP-1a (rMIP). Immunoreactive bands of the same estimated
molecular mass were present in concentrated CM samples of cytotropho-
blasts isolated from first (I), second (II), and third (III) trimester placentas,
but not the control SFM. (B) MIP-1a concentrations in cytotrophoblast
CM as assessed by ELISA. CM was harvested from first trimester, second
trimester, and term cells that were cultured for 12–48 h. Levels of this
chemokine detected in individual samples ranged from 1.2–82 ng/ml.
The five sets of connected data points show MIP-1a levels in medium
samples from the same culture over time, demonstrating that the protein
accumulated in the medium during the course of the experiment. As ex-
pected, MIP-1a was not detected in control SFM/MG or placental fibro-
blast CM (data not shown).
Figure 6. Invasive cytotrophoblasts express MIP-1a mRNA in vivo. In
situ hybridization on tissue sections of the maternal–fetal interface at term
demonstrates the presence of MIP-1a mRNA in cytotrophoblasts within
the uterine wall. (A) Bright field micrograph of a histological section that
was stained with hematoxylin and eosin (HE). Clusters of cytotrophoblasts
are easily seen within a loose meshwork of extracellular matrix compo-
nents. (B) Dark field micrograph of the same section. White dots indicate
signal from 35S-labeled MIP-1a antisense probe (8-wk exposure). This
signal is absent in an adjacent section (C) that was incubated with sense
probe as a negative control. AV, anchoring villus.1206 Human Placental Cells Use Chemokines to Recruit Monocytes and NK Cells
concentration by ELISA. There was no correlation be-
tween the two variables, as determined by the Spearman
Rank Order Correlation test (data not shown). This result
shows that cytotrophoblasts are the source of MIP-1a pro-
tein in the medium.
Cytotrophoblasts Express MIP-1a mRNA and Protein In
Vivo. As a final step in assessing cytotrophoblast production
of MIP-1a, we examined cytotrophoblasts in tissue sec-
tions of the maternal–fetal interface using in situ hybridiza-
tion to detect mRNA (Fig. 6) and immunofluorescence to
detect protein (Fig. 7). Fig. 6 A shows a photomicrograph
of a histological section that was stained with hematoxylin
and eosin. The morphology is typical of the uterine wall at
term—the cytotrophoblasts lie within a loose meshwork of
extracellular matrix components. In situ hybridization of
these tissue sections with 35S-labeled antisense probe (Fig. 6
B) revealed MIP-1a mRNA expression by cells within an-
choring villi and by extravillus cytotrophoblasts within the
uterine wall (n 5 9). As a negative control, adjacent sec-
tions were hybridized with sense probe (Fig. 6 C), which
yielded no signal. Complementary evidence was obtained
by immunofluorescence localization (n 5 4). Cytokeratin
expression was used to identify cytotrophoblasts within the
uterine wall (Fig. 7 A). Adjacent sections demonstrated that
these cells stain with anti–MIP-1a (Fig. 7 B), suggesting
their production of this protein in vivo. The specificity of
this pattern was confirmed by the absence of staining when
specimens were incubated with normal goat serum as a
negative control (Fig. 7 D).
MIP-1a in Cytotrophoblast CM Induces the Migration of
Monocytes and CD56bright NK Cells. Having shown that
cytotrophoblasts produce MIP-1a, we assessed the contri-
bution of this chemokine to the CM activity originally ob-
served: induction of monocyte, NK cell, and T cell
chemotaxis. First, we performed control experiments to
characterize the chemotactic activity of MIP-1a in our sys-
tem, using recombinant chemokine with unstimulated
PBMCs as targets (Fig. 8). A range of concentrations that
encompassed those found in cytotrophoblast CM was tested.
This control system also allowed us to demonstrate the effi-
cacy of the function-perturbing anti–MIP-1a antibody that
was used in subsequent experiments.
The results showed that the response to recombinant
MIP-1a varied among the various PBMC populations we
analyzed. As reported by other investigators (52), large
numbers of monocytes migrated in every experiment (n 5
8). The results of a typical analysis are shown in Fig. 8 A.
Monocyte chemotaxis peaked at a MIP-1a concentration
of 10 ng/ml, addition of anti–MIP-1a returned migration
to baseline levels, and a control IgG antibody added at the
same concentration had no effect. NK cells also responded
to recombinant MIP-1a, although somewhat less consis-
tently. In six out of nine experiments, CD56bright and
CD56dim NK cells migrated toward recombinant MIP-1a
(Fig. 8, B and C, respectively). Again, chemotaxis was not
observed in the presence of anti–MIP-1a. Finally, the ef-
fects of MIP-1a on T cells were highly variable. In three of
nine experiments, we observed chemotaxis that was re-
versed by the addition of anti–MIP-1a (data not shown).
Next we assayed the chemotactic activity of cytotropho-
blast CM, using PBMCs as targets. In these experiments,
MIP-1a in cytotrophoblast CM was quantified by ELISA,
and then the medium was diluted to produce CM samples
that contained from 100 ng/ml to 10 pg/ml of this
chemokine. The chemoattractant activity of these CM
samples is summarized in Fig. 9 A.
Monocyte migration toward cytotrophoblast CM typi-
cally peaked at 10 ng/ml of MIP-1a (six of eight times), as
did the migration of these cells in response to the recombi-
nant chemokine (compare Fig. 8 A and Fig. 9 A). At the
Figure 7. Invasive cytotropho-
blasts express protein MIP-1a in
vivo. Immunohistochemistry on tis-
sue sections of the maternal–fetal in-
terface identifies cytokeratin (CK)-
positive invasive cytotrophoblasts
within the uterine wall (A). Staining
of an adjacent section reveals that
these invasive cytotrophoblasts ex-
press MIP-1a protein (B). The spec-
ificity of the MIP-1a pattern was es-
tablished by staining with normal
goat serum as a negative control.
Other specimens were exposed to
(C) an anticytokeratin antibody,
which demonstrated the cytotro-
phoblasts within the tissue, and (D)
to the control serum, which did not
yield a signal. NGS, normal goat se-
rum; V, chorionic villus.1207 Drake et al.
peak, 16% (3–53%) of all monocytes migrated (median and
interquartile range; n 5 8). Since the Matrigel extracellular
matrix preparation is a potential source of chemoattractants,
basal migration toward medium that was incubated with
the matrix substrate in the absence of cells (SFM/MG) was
also tested. In this control situation, 1.5% (0.5–5%) of the
cells migrated. Taken together, these data showed that cy-
totrophoblast CM stimulated a sevenfold (3.7- to 16.6-
fold) increase in migration over control levels.
Cytotrophoblast CM also attracted CD56dim and
CD56bright NK cells. In all but one instance (eight out of
nine times), NK cell migration was still increasing at the
highest CM (MIP-1a) concentration that was tested (Fig. 9
A). At this point 4% (0.6–5%) of all CD56dim cells and 5.4%
(1.8–10.5%) of all CD56bright cells migrated. Basal migration
stimulated by control medium was similar for both NK
subtypes: 0.4% (0.1–0.9%) for CD56dim cells and 0.6%
(0.2–1%) for CD56bright cells. Thus, cytotrophoblast CM
induced a 7.7-fold increase (5- to 12-fold) in the migration
of CD56dim cells and a 5.5-fold increase (2.8- to 6.5-fold)
in the migration of CD56bright cells.
The pattern of T cell migration in response to cytotro-
phoblast CM followed that of NK cells, i.e., a peak was not
observed within the range of cytotrophoblast CM (MIP-
1a) concentrations tested (Fig. 9 A). At the highest con-
centration, 1.7% (1.3–3.5%; n 5 9) of T cells migrated as
compared with basal migration, which was 0.5% (0.4–
1.22%). Accordingly, cytotrophoblast CM increased T cell
migration by twofold (1.7- to 4-fold) over basal levels, a
relatively modest response compared with that of mono-
cytes and NK cells.
Finally, we analyzed the effects of adding function-per-
turbing anti–MIP-1a on cytotrophoblast CM-induced
PBMC chemotaxis. In five experiments, neutralizing MIP-
1a activity reduced monocyte migration at its peak by
44.2 6 10.0% (mean 6 SD) as compared with the addition of
a control IgG. Fig. 9 B shows the results of a typical analysis.
Here and subsequently we used a two-tailed Student’s t test
to further analyze the data from individual experiments.
The results of three experiments achieved statistical signifi-
cance (P , 0.05). Data from the other two experiments
were less significant (P , 0.075 and P , 0.20). In four ex-
periments, abolishing MIP-1a activity in the CM reduced
migration of CD56bright NK cells by 66.8 6 20.0% as com-
pared with the control IgG. An example of these data is
shown in Fig. 9 C. The results of three experiments were
highly significant (P , 0.005). In one case, the data were
less significant (P , 0.1). Although cytotrophoblast CM
Figure 8. The effects of recombinant MIP-1a on PBMC chemotaxis.
(A–C) Results of a representative experiment. (A) Monocyte chemotaxis
toward a dilution series of recombinant MIP-1a (rMIP-1a) peaked at a
concentration of 10 ng/ml. Addition of a neutralizing anti–MIP-1a IgG
(NIgG) returned migration to baseline levels, and a control IgG antibody
(CIgG) added at the same concentration had no effect. (B) CD56bright and
(C) CD56dim NK cells also responded to recombinant MIP-1a, but their
migration did not peak within the range of concentrations tested. Addition
of anti–MIP-1a reduced NK cell migration to baseline.1208 Human Placental Cells Use Chemokines to Recruit Monocytes and NK Cells
Figure 9. Cytotrophoblast CM attracts monocytes and
CD56bright NK cells via the action of MIP-1a. Panels A–C de-
pict the results of a representative experiment. MIP-1a levels in
cytotrophoblast CM samples were determined by ELISA. The
chemoattractant activity of cytotrophoblast CM that contained
from 0.01 to 100 ng/ml MIP-1a is summarized in A. In all ex-
periments, the migration of cells toward SFM that was incubated
with Matrigel alone (SFM/MG) was used to assess basal migra-
tion. Monocyte movement toward the CM peaked at 10 ng/ml
of MIP-1a, while NK cell and T cell migration was still increas-
ing at the highest concentration of CM (chemokine) tested. (B
and C) Addition of a neutralizing anti–MIP-1a IgG (NIgG) sig-
nificantly reduced the migration of PBMCs toward cytotropho-
blast CM. (B) At its peak, monocyte migration was reduced by
44.2 6 10.0% (mean 6 SD) as compared to the addition of a
control IgG (CIgG). (C) Chemotaxis of CD56bright NK cells was
diminished by 66.8 6 20.0% as compared to the control IgG.
Neither CD56dim NK cell nor T cell migration was affected by
neutralization of MIP-1a activity (data not shown).1209 Drake et al.
was chemotactic for both CD56dim NK cells and T cells,
antibody neutralization showed that this effect did not de-
pend on MIP-1a activity, suggesting a more complex phe-
nomenon (data not shown).
Discussion
The mechanisms whereby the human hemiallogeneic
placenta avoids rejection by the maternal immune system
are under intense investigation. In accord with the central
role of placentation in pregnancy maintenance, current ev-
idence suggests multiple levels of regulation. There are sev-
eral notable examples in which fetal trophoblasts produce
soluble factors with activities that have the potential to
modify maternal immune functions. These molecules in-
clude cytokines and growth factors, such as IL-10 (53),
TGF-b (54, 55), and MIF (56), that downregulate immu-
nological responses in other settings (57–59). Interestingly,
the placenta has also adopted strategies to regulate the im-
mune system at a metabolic level by producing the enzyme
indoleamine 2,3-dioxygenase, which catabolizes trypto-
phan needed by activated T cells (60). Finally, several novel
mechanisms of immune regulation are used at the mater-
nal–fetal interface, including high local levels of progester-
one (61) and expression of the nonclassical MHC class I
molecule HLA-G (7), which also has a soluble form. All of
these products downregulate the immune response, partic-
ularly the activities of T cells and NK cells, the primary
mediators of allogeneic graft rejection.
We now add chemokines, regulators of leukocyte traf-
ficking, to the list of placenta-derived immunomodulators.
In this report, we demonstrate that cytotrophoblasts express
chemokines that can direct the migration of leukocytes
similar to those found at the maternal–fetal interface. In
vitro chemotaxis assays characterized the effects of cytotro-
phoblast CM on PBMCs. The chemotactic responses of
the target cells to the CM resembled those observed when
leukocytes are challenged with chemokines, in terms of
concentration dependence, time course, and efficacy with
regard to cell number (62–64). Accordingly, we used re-
porter cells transfected with specific receptors to test for the
presence of chemokines in the medium. This assay revealed
the presence of MIP-1a, a result we confirmed by comple-
mentary analyses at both the RNA and protein levels.
Freshly isolated cytotrophoblast stem cells expressed very
low amounts of MIP-1a mRNA, although expression in-
creased dramatically as the cells differentiated in culture.
This suggested that in vivo, cytotrophoblasts upregulate the
expression of this chemokine as they differentiate/invade
the uterine wall (Fig. 1). In situ hybridization and immu-
nofluorescence analyses of tissues that contained the mater-
nal–fetal interface confirmed that cytotrophoblasts inside
the uterine wall express MIP-1a mRNA and protein in
vivo. Although the production of MIP-1a by cytotropho-
blasts in vitro was highly reproducible, the concentration of
secreted chemokine varied among cell preparations, rang-
ing from ,175 pg/ml to 82 ng/ml in the CM. This finding
correlates with similar observations of variability in cyto-
kine (e.g., IL-10) and hormone (e.g., placental lactogen)
production among different placentas (53, 65, 66). Because
each individual is the product of a unique genetic, hor-
monal, and immunological environment, it follows that
production of downstream effector molecules by tissues
from individual donors reflects these differences.
In spite of this variability in chemokine production, spe-
cific aspects of the chemotactic properties of cytotropho-
blast CM were clearly attributable to the presence of MIP-
1a, as eliminating its activity from the cytotrophoblast CM
altered the chemotaxis of target cells in our in vitro assay.
In general, these effects reflected the previously published
actions of this chemokine on leukocyte subsets. For exam-
ple, MIP-1a in the cytotrophoblast medium strongly at-
tracted monocytes, well established targets for this mole-
cule (52). The fact that the dose–response curves for
monocyte chemotaxis toward cytotrophoblast CM and re-
combinant MIP-1a were essentially superimposable sug-
gested that this chemokine was a dominant cytotro-
phoblast-derived factor regulating monocyte migration.
Additionally, in terms of absolute cell numbers, cytotro-
phoblast CM stimulated migration of z15% of the target
monocytes, and addition of anti–MIP-1a to cytotropho-
blast CM reduced monocyte migration by z45%. To-
gether, these data indicate that cytotrophoblasts rely heavily
on MIP-1a in the CM to regulate monocyte chemotaxis.
Other cytotrophoblast-derived chemokines, such as RANTES,
may also contribute to this phenomenon (67).
Cytotrophoblast CM was also highly chemotactic for
NK cells, another established target of MIP-1a (63, 68). As
the NK cells that reside in the uterus during pregnancy are
of the CD56bright rather than the CD56dim phenotype, we
analyzed the chemotaxis of each population of cells sepa-
rately. As CD56bright cells comprise only 10% of all circulat-
ing NK cells, most studies investigating chemokine activity
have not distinguished between the two subtypes. One ex-
ception is the report that secondary lymphoid chemokine
and CKb-11, both ligands for the CCR7 receptor, prefer-
entially attract CD56bright over CD56dim cells (69). Here,
we report that MIP-1a activity in cytotrophoblast CM is
responsible for nearly 70% of the migration of CD56bright
cells we observed. In contrast, the contribution of this
chemokine to the migration of CD56dim cells is less clear,
suggesting that other factors in cytotrophoblast CM may be
responsible for this activity. Therefore, in this system MIP-
1a has differential effects on these two NK subsets. Thus,
via MIP-1a, cytotrophoblasts are equipped with a potent
mechanism that may allow them to direct the movement of
the two major populations of leukocytes, monocytes and
CD56bright NK cells, with which they interact at the mater-
nal–fetal interface.
Finally, although MIP-1a is a reported attractant for ac-
tivated T cells, it was not responsible for the migration of
these cells toward cytotrophoblast CM. In accord with pre-
viously published data, the unstimulated T cells within our
PBMC target population did not migrate toward recombi-
nant MIP-1a (70). Similarly, the migration of unstimulated
T cells toward cytotrophoblast CM was not affected by ad-1210 Human Placental Cells Use Chemokines to Recruit Monocytes and NK Cells
dition of anti–MIP-1a to the medium. These findings sug-
gest the presence in the CM of T cell chemoattractants
whose identity we have not yet established.
This report demonstrates that cytotrophoblasts may be
capable of contributing to the recruitment of decidual leu-
kocytes. It should be noted that the uterine stroma itself is
capable of attracting circulating leukocytes, as distinct pop-
ulations of immune cells migrate through the uterus during
the course of the menstrual cycle (71). Furthermore, decid-
ual leukocytes can be found in the decidua in the event of
an ectopic pregnancy, when the placenta has implanted
outside of the uterus (72). Therefore, decidual leukocyte
infiltration is also regulated by the decidual vasculature, as is
suggested by the highly specific combinatorial expression of
adhesion molecules in pregnant mouse uterine blood ves-
sels (73). These adhesion molecules are integral to a multi-
step homing process that also requires chemokines. In
mice, the absence of MIP-1a or one of its receptors
(CCR5) did not affect NK cell infiltration of the pregnant
uterus (74). Given the number of known chemokines and
receptors, it is likely that mice and humans employ distinct
sets of these molecules to influence decidual leukocyte che-
motaxis.
Here, we demonstrate that the human cytotrophoblasts
produce MIP-1a, which endows them with the capacity to
direct the migration of NK cells, monocytes, and T cells,
cells that comprise the DGL population with which the pla-
centa coexists. This activity could contribute to the recruit-
ment of decidual leukocytes or may be used at a local level
to manipulate the microimmune environment at the mater-
nal–fetal interface. Either scenario affords fetal cytotropho-
blasts an additional level of control in regulating the im-
mune activity of maternal cells in this sensitive location.
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